Abstract
Background: Stenotrophomonas maltophilia (SM) is a Gram-negative non-fermenting bacteria cultured from the sputum of patients with cystic fibrosis (CF). To date, no information is available regarding the effect of this organism on lung function in CF.
Methods: A cohort study was conducted to assess the effect of SM on lung function among CF patients aged ⩾6 years in the CF Foundation National Patient Registry from 1994 to 1999. Repeated measures regression was used to assess the association between SM and lung function.
Results: The cohort consisted of 20 755 patients with median age at entry of 13.8 years and median follow up time of 3.8 years; 2739 patients (13%) were positive at least once for SM and 18 016 (87%) were never positive. After adjusting for sex, height and age, patients with SM had a mean forced expiratory volume in 1 second which was 0.09 l less (95% CI 0.05 to 0.14) than those without SM. The mean rate of decline associated with SM positivity was 0.025 l/year (95% CI 0.012 to 0.037) but, after adjusting for confounders (sex, height, weight, intravenous antibiotic courses, hospital admissions, pancreatic insufficiency, and Pseudomonas aeruginosa and Burkholderia cepacia status), the mean rate of decline decreased to 0.008 l/year (–0.008, 95% CI –0.019 to 0.003).
Conclusions: Although CF patients with SM have worse lung function at the time of positivity, no association was found between SM and increased rate of decline after controlling for confounders.
Full Text
The Full Text of this article is available as a PDF (135.5 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bauernfeind A., Emminger G., Hörl G., Ott S., Przyklenk B., Weisslein-Pfister C. Bacteriological effects of anti-Pseudomonas aeruginosa chemotherapy in cystic fibrosis. Infection. 1987;15(5):403–406. doi: 10.1007/BF01647753. [DOI] [PubMed] [Google Scholar]
- Burns J. L., Emerson J., Stapp J. R., Yim D. L., Krzewinski J., Louden L., Ramsey B. W., Clausen C. R. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis. 1998 Jul;27(1):158–163. doi: 10.1086/514631. [DOI] [PubMed] [Google Scholar]
- Demko C. A., Stern R. C., Doershuk C. F. Stenotrophomonas maltophilia in cystic fibrosis: incidence and prevalence. Pediatr Pulmonol. 1998 May;25(5):304–308. doi: 10.1002/(sici)1099-0496(199805)25:5<304::aid-ppul3>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
- Denton M., Kerr K. G. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev. 1998 Jan;11(1):57–80. doi: 10.1128/cmr.11.1.57. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Denton M., Todd N. J., Littlewood J. M. Role of anti-pseudomonal antibiotics in the emergence of Stenotrophomonas maltophilia in cystic fibrosis patients. Eur J Clin Microbiol Infect Dis. 1996 May;15(5):402–405. doi: 10.1007/BF01690098. [DOI] [PubMed] [Google Scholar]
- FitzSimmons S. C. The changing epidemiology of cystic fibrosis. J Pediatr. 1993 Jan;122(1):1–9. doi: 10.1016/s0022-3476(05)83478-x. [DOI] [PubMed] [Google Scholar]
- Gladman G., Connor P. J., Williams R. F., David T. J. Controlled study of Pseudomonas cepacia and Pseudomonas maltophilia in cystic fibrosis. Arch Dis Child. 1992 Feb;67(2):192–195. doi: 10.1136/adc.67.2.192. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Goss Christopher H., Otto Kelly, Aitken Moira L., Rubenfeld Gordon D. Detecting Stenotrophomonas maltophilia does not reduce survival of patients with cystic fibrosis. Am J Respir Crit Care Med. 2002 Aug 1;166(3):356–361. doi: 10.1164/rccm.2109078. [DOI] [PubMed] [Google Scholar]
- Graff Gavin R., Burns Jane L. Factors affecting the incidence of Stenotrophomonas maltophilia isolation in cystic fibrosis. Chest. 2002 Jun;121(6):1754–1760. doi: 10.1378/chest.121.6.1754. [DOI] [PubMed] [Google Scholar]
- Karpati F., Malmborg A. S., Alfredsson H., Hjelte L., Strandvik B. Bacterial colonisation with Xanthomonas maltophilia--a retrospective study in a cystic fibrosis patient population. Infection. 1994 Jul-Aug;22(4):258–263. doi: 10.1007/BF01739911. [DOI] [PubMed] [Google Scholar]
- Krzewinski J. W., Nguyen C. D., Foster J. M., Burns J. L. Use of random amplified polymorphic DNA PCR to examine epidemiology of Stenotrophomonas maltophilia and Achromobacter (Alcaligenes) xylosoxidans from patients with cystic fibrosis. J Clin Microbiol. 2001 Oct;39(10):3597–3602. doi: 10.1128/JCM.39.10.3597-3602.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rajan Sujatha, Saiman Lisa. Pulmonary infections in patients with cystic fibrosis. Semin Respir Infect. 2002 Mar;17(1):47–56. doi: 10.1053/srin.2002.31690. [DOI] [PubMed] [Google Scholar]
- Rosenstein B. J., Cutting G. R. The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. J Pediatr. 1998 Apr;132(4):589–595. doi: 10.1016/s0022-3476(98)70344-0. [DOI] [PubMed] [Google Scholar]
- Shreve M. R., Butler S., Kaplowitz H. J., Rabin H. R., Stokes D., Light M., Regelmann W. E. Impact of microbiology practice on cumulative prevalence of respiratory tract bacteria in patients with cystic fibrosis. J Clin Microbiol. 1999 Mar;37(3):753–757. doi: 10.1128/jcm.37.3.753-757.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Tablan O. C., Chorba T. L., Schidlow D. V., White J. W., Hardy K. A., Gilligan P. H., Morgan W. M., Carson L. A., Martone W. J., Jason J. M. Pseudomonas cepacia colonization in patients with cystic fibrosis: risk factors and clinical outcome. J Pediatr. 1985 Sep;107(3):382–387. doi: 10.1016/s0022-3476(85)80511-4. [DOI] [PubMed] [Google Scholar]
- Talmaciu I., Varlotta L., Mortensen J., Schidlow D. V. Risk factors for emergence of Stenotrophomonas maltophilia in cystic fibrosis. Pediatr Pulmonol. 2000 Jul;30(1):10–15. doi: 10.1002/1099-0496(200007)30:1<10::aid-ppul3>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]